Jpmorgan Chase & CO Mustang Bio, Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.32 - $8.27 $7,092 - $183,296	-22,164 Reduced 91.67%	2,015 $1,000
Q3 2022 Nov 14, 2022	SELL	$0.46 - $7.2 $700,606 - $11 Million	-1,523,057 Reduced 98.44%	24,179 $12,000
Q2 2022 Aug 11, 2022	SELL	$0.58 - $1.13 $352,200 - $686,184	-607,243 Reduced 28.19%	1,547,236 $905,000
Q1 2022 May 11, 2022	SELL	$0.73 - $1.81 $104,232 - $258,439	-142,784 Reduced 6.22%	2,154,479 $2.18 Million
Q4 2021 Feb 10, 2022	BUY	$1.66 - $2.64 $5,028 - $7,996	3,029 Added 0.13%	2,297,263 $3.81 Million
Q3 2021 Nov 12, 2021	BUY	$2.58 - $3.36 $5.92 Million - $7.71 Million	2,294,234 New	2,294,234 $6.17 Million

415K

Ticker MBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,222,000
Market Cap $22.1M
Description
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.